Business Context and Reporting Period
This Form 8-K Current Report is filed by 180 Life Sciences Corp. (not Forum Markets Inc.) for the reporting period ending October 24, 2024. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and adjustments to board committee structures.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel and governance matters.
Material Changes
- Board Appointment: Jay Goodman was appointed as a Class I Director effective October 24, 2024, serving until the 2025 Annual Meeting.
- Board Size: The Board of Directors increased the number of members to five (5).
- Committee Assignments: Mr. Goodman was appointed to the Audit Committee and the Nominating and Corporate Governance Committee. He was named Chairman of the Compensation Committee.
- Related Party Context: Mr. Goodman is the adult son of Anthony Brian Goodman, CEO of Elray Resources, Inc. Elray Resources holds 1,000,000 shares of the Company's Series B Convertible Preferred Stock, convertible into 40% of the Company's then-outstanding common stock, and warrants to purchase 3,000,000 shares at $1.68 per share.
- Termination of Prior Agreement: The Offer Letter for Blair Jordan (Interim CEO) regarding his independent director role was mutually terminated as he is no longer serving as an independent member of the Board.
Guidance, Outlook, and Compensation
Compensation Arrangements:
- Annual Retainer: $50,000 for Board service.
- Committee Chair Fee: $15,000 for Chairing the Compensation Committee.
- Payment Terms: Paid quarterly in arrears, pro-rated for partial quarters. Mr. Goodman may elect to receive 50% in cash and 50% in stock, or 100% in cash.
- Indemnification: The Company plans to enter a standard Indemnity Agreement with Mr. Goodman.
Outlook and Risks: The filing notes that the conversion of Elray Resources' preferred stock and the exercise of warrants are subject to stockholder approval under applicable Nasdaq rules. No specific financial guidance or operational outlook was provided in this document.
Investor Verification Checklist
- Verify the status of stockholder approval required for the conversion of Elray Resources' Series B Convertible Preferred Stock and warrant exercise.
- Confirm the total number of outstanding shares to calculate the precise dilution impact of the 40% conversion mentioned.
- Review the attached Offer Letter (Exhibit 10.1) for any additional terms not summarized in the filing.
- Monitor future filings for the engagement details of the Senior Technology Consultant mentioned in the press release (Exhibit 99.1).